Studies in mice with cardiomyocyte-restricted inactivation of the MR gene suggest that the clinical benefits of MR blocking therapy in MI and heart failure are mediated largely via cardiomyocyte-dependent mechanisms (46). This evidence concerns the gene NR3C2 and heart failure.